Blombäck M - Search Results

1

Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.

Ågren A, Holmström M, Schmidt DE, Hosokawa K, Blombäck M, Hjemdahl P. Ågren A, et al. Among authors: blomback m. Thromb Haemost. 2017 Jan 5;117(1):75-85. doi: 10.1160/TH16-06-0430. Epub 2016 Oct 20. Thromb Haemost. 2017. PMID: 27761577

2

Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma.

Antovic A, Blombäck M, Sten-Linder M, Petrini P, Holmström M, He S. Antovic A, et al. Among authors: blomback m. Blood Coagul Fibrinolysis. 2005 Nov;16(8):585-96. doi: 10.1097/01.mbc.0000188411.94740.d7. Blood Coagul Fibrinolysis. 2005. PMID: 16269934

3

Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin.

Li N, He S, Blombäck M, Hjemdahl P. Li N, et al. Among authors: blomback m. Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):407-13. doi: 10.1161/01.ATV.0000253906.19648.ac. Epub 2006 Nov 30. Arterioscler Thromb Vasc Biol. 2007. PMID: 17138937 Clinical Trial.

4

A ROTEM method using APTT reagent and tissue factor as the clotting activators may better define bleeding heterogeneity in moderate or severe haemophilia A (part I: Study in plasma samples).

He S, Eelde A, Petrini P, Wallen H, Gabrielsson L, Svensson J, Blombäck M, Holmström M. He S, et al. Among authors: blomback m. Thromb Res. 2018 Nov;171:7-13. doi: 10.1016/j.thromres.2018.09.041. Epub 2018 Sep 5. Thromb Res. 2018. PMID: 30216822

5

Fifth Åland Island conference on von Willebrand disease.

Berntorp E, Ågren A, Aledort L, Blombäck M, Cnossen MH, Croteau SE, von Depka M, Federici AB, Goodeve A, Goudemand J, Mannucci PM, Mourik M, Önundarson PT, Rodeghiero F, Szántó T, Windyga J. Berntorp E, et al. Among authors: blomback m. Haemophilia. 2018 May;24 Suppl 4:5-19. doi: 10.1111/hae.13475. Haemophilia. 2018. PMID: 29687935 Free article.

6

Marked increase of fibrin gel permeability with very low dose ASA treatment.

Antovic A, Perneby C, Ekman GJ, Wallen HN, Hjemdahl P, Blombäck M, He S. Antovic A, et al. Among authors: blomback m. Thromb Res. 2005;116(6):509-17. doi: 10.1016/j.thromres.2005.02.007. Thromb Res. 2005. PMID: 16181986

7

von Willebrand factor in plasma and urine of men with premature coronary artery disease.

Silveira AM, Elgue G, Hamsten A, Blombäck M. Silveira AM, et al. Among authors: blomback m. Thromb Haemost. 1992 Jan 23;67(1):161-5. Thromb Haemost. 1992. PMID: 1615472

8

Validation of a composite score for clinical severity of hemophilia.

Schulman S, Eelde A, Holmström M, Ståhlberg G, Odeberg J, Blombäck M. Schulman S, et al. Among authors: blomback m. J Thromb Haemost. 2008 Jul;6(7):1113-21. doi: 10.1111/j.1538-7836.2008.03001.x. Epub 2008 Jul 1. J Thromb Haemost. 2008. PMID: 18466317 Free article.

9

Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid.

Williams S, Fatah K, Hjemdahl P, Blombäck M. Williams S, et al. Among authors: blomback m. Eur Heart J. 1998 Nov;19(11):1666-72. doi: 10.1053/euhj.1998.1088. Eur Heart J. 1998. PMID: 9857919

10

Haemostatic, endothelial and lipoprotein parameters and blood pressure levels in women with a history of preeclampsia.

He S, Silveira A, Hamsten A, Blombäck M, Bremme K. He S, et al. Among authors: blomback m. Thromb Haemost. 1999 Apr;81(4):538-42. Thromb Haemost. 1999. PMID: 10235435

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

363 results

Search Page